New Parkinson’s Disease Research Maps Out Inhibitory Processes

Neurotransmission pic

Neurotransmission
Image: oist.jp

As CEO of Consonance Capital, Dr. Mitchell Blutt guides private equity funds and health care investments. Community focused, Dr. Mitchell Blutt supports a number of nonprofits and is a past board member of the Michael J. Fox Foundation, which is working to find a cure for Parkinson’s disease.

Impacting 10 million people across the globe, Parkinson’s disease is a neurological condition that results in deterioration of physical function, with uncontrollable tremors leading to nerve cells misfiring and dying within the brain. Still incurable, Parkinson’s disease is not fully understood by medical researchers.

A recently published study by the Okinawa Institute of Science and Technology Graduate University revealed the protein that blocks the proper transmission of neural signals that underpin higher brain functioning. Neurotransmission enables neurons to communicate signals effectively and transfer them in ways that allow seamless sensory motor functioning.

The chemical messengers contained in vesicle endocytosis within the nerve terminal are essential in transmitting neurological signals. When the process of endocytosis is inhibited during times of heavy use, processes breakdown and sensory perception of motor control is affected. Understanding this inhibitory process promises to offer a vital step toward tailoring treatments to actual neurological conditions in ways that have a positive for among patients.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s